PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32642151-0	2020	Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial.	Docetaxel	28-37	epidermal growth factor receptor	Homo sapiens	123-127	
32642151-11	2020	Conclusions: Apatinib plus docetaxel is an effective and tolerable treatment option for advanced non-squamous NSCLC with wild-type EGFR.	Docetaxel	27-36	epidermal growth factor receptor	Homo sapiens	131-135